Free Shipping on Orders $150+

For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.

CJC-1295 no DAC + Ipamorelin

4.9 (157)

Growth Hormone Secretagogue Blend

Dosage

Quantity

1

Price

$53.99

Free shipping on orders $150+

60-day money-back guarantee

Secure checkout

Made in the USA

Certificate of Analysis

Batch verified lab data

Latest

99.93%

Purity

Variant
CJC-1295 no DAC + Ipamorelin 10mg (5+5)
Lot #
A0112
Labeled
20mg
Actual
22.56mg
Tested
Feb 4, 2026

Frequently Researched Together

View all

Semaglutide

Metabolic Research Peptide

$34.99

View

GHK-Cu

Anti-Aging Compound

$26.99

View

NAD+

Longevity Research Compound

$62.99

View

MOTS-c

Metabolic & Longevity Peptide

$34.99

View

Research Purposes Snapshot

Educational synthesis of published GHRH-analog and GHRP-class secretagogue work (including CJC-1295 without DAC and ipamorelin). Figures come from cited human studies and reviews—not a dosing guide for this listing.

~54×

Peak GH signal

Combined GHRH + GHRP-class stimulation vs baseline in classic infusion models.

~2.7×

Synergy factor

Whole-axis response exceeds either receptor arm alone in published co-administration curves.

Selective

GH release

Ipamorelin narratives emphasize GH release without meaningful cortisol or prolactin excursions at studied doses.

30–120 min

Half-life cue

CJC-1295 without DAC clears faster than albumin-conjugated forms—shorter plasma exposure, more pulsatile-friendly.

Pulsatile

GH pattern

No-DAC pharmacokinetics align with intermittent pituitary stimulation rather than flat GH plateaus.

Blend information

Why this combination

Synergistic GH releaseDual-pathway activationPulsatile pattern preserved
Typical ratio
1:1 by weight (formulation-dependent)
Functional half-life window
~1–2 hours (combined acute effect)
Synergy vs single pathway
~2.7× (literature shorthand)
Route
Subcutaneous (trial context)

Review framing: Sigalos & Pastuszak, 2018 — verify dosing in primary papers.

Key mechanism

Why the combination works

GHRH-mimetic and GHRP-class ligands engage distinct receptor systems on somatotrophs. Co-stimulation stacks intracellular signals so peak GH output exceeds simple addition—often quoted as synergistic rather than additive.

Synergy demonstrated: benchmark infusion work reports ~20× GH with GHRH-class pulses alone, ~47× with select GHRP-class pulses alone, and ~54× when both arms are combined, with ~43% faster time-to-peak GH versus GHRH alone (Bowers et al., 1991 — model-dependent).
  • GHRH pathway alone~20× GH
  • GHRP-class pathway alone~47× GH
  • Combined pathways~54× GH
  • Time to peak GH↓ ~43%

Selectivity advantage

Why ipamorelin is discussed differently

Ipamorelin is frequently described as a comparatively selective secretagogue: at GH-releasing doses it generally does not reproduce the cortisol, ACTH, or prolactin spikes reported for older GHRP chemotypes (e.g., GHRP-2, GHRP-6, hexarelin).

Clinical significance: reduced appetite drive, fluid retention, and stress-hormone noise relative to non-selective GHRP narratives—still map every claim to the exact dose cohort.

Phase I/II & mechanistic context

GH / IGF-1 axis readouts

~54× peak GH (combined)

Modeled pathway strength (illustrative)

GHRH + GHRP combined~54×
GHRP-class alone~47×
GHRH-class alone~20×
  • CJC-1295 without DAC: dose-dependent GH increases commonly quoted in the ~2–10× range depending on cohort.
  • IGF-1 may remain elevated ~1.5–3× baseline for ~9–11 days after single doses in healthy-volunteer summaries.
  • Ipamorelin selectivity statements rely on hormone panels from defined infusion studies.

Clinical findings snapshot

Responder & hormone panels

Subjects with significant GH rise (CJC-1295 trials, narrative)100%
Meaningful cortisol spike at GH doses (ipamorelin panels)0%

IGF-1 duration cue

After single CJC-1295 exposures, reviewers cite ~9–11 days of above-baseline IGF-1 in healthy adults.

No-DAC CJC-1295 preserves pulsatile GH morphology in pharmacodynamic discussions; ipamorelin acts as selective amplification of the GHRP arm.

CJC-1295 without DAC — axis emphasis

Peak hormone vs duration trade-off

  • Peak GH (high-dose cohorts)Near-maximal vs protocol max
  • IGF-1 elevationUp to ~300% of baseline (~3×) in cited summaries
  • Duration of IGF-1 signal~11 days (upper range of 9–11 day window)

Summaries derive from healthy-adult pharmacology studies. Shorter CJC-1295 half-life without DAC is framed as more physiologic pulsatility versus depotized analogs—always read the primary pharmacokinetic curve.

Beyond acute GH release

Review-level benefits attributed to GH/IGF-1 secretagogue exposure

IGF-1 peak

~1.3×

Peak IGF-1 after CJC-1295 in Teichman et al., 2006.

Kinetics

43% faster

Time-to-peak GH when GHRH + GHRP co-stimulated (Bowers et al., 1991).

Pattern

Pulsatile

No-DAC CJC-1295 preserves burst-like release in PD reviews (Teichman et al., 2006).

Tolerability

Favorable

Ipamorelin acute studies (Raun et al., 1998) report predictable, dose-related events.

Body composition

Lean mass & fat balance

Reviews link GH/IGF-1 increments to lipolysis and protein anabolism—mechanistic, not a guarantee in any given lab model.

  • Lean body mass↑ discussed
  • Fat mass↓ discussed
  • Protein synthesis↑ emphasized
  • Resting metabolism↑ variable

Review angle: pulsatile secretagogue patterns are argued to mirror natural GH physiology more closely than continuous exposure (Sigalos & Pastuszak, 2018).

Recovery narratives

Tissue repair themes

GH/IGF-1 elevation is associated with collagen and connective-tissue turnover in consensus statements—figures below are illustrative review shorthand, not trial endpoints for this SKU.

Collagen synthesis (review scale)85%
Muscle recovery (review scale)80%
Connective tissue repair (review scale)75%

Growth Hormone Research Society summaries — verify in specialty texts.

Sleep quality

Slow-wave sleep correlation

Evening secretagogue administration is discussed alongside deeper slow-wave sleep in some endocrine reviews—effect sizes depend on population and sleep staging method.

Slow-wave sleep duration

Framed as aligning with the natural nocturnal GH surge.

Clinical correlation: GH peaks during deep sleep; secretagogue timing is debated to reinforce that rhythm (Sigalos & Pastuszak, 2018).

Age-related GH decline

Secretagogue rationale in older adults

Endogenous GH secretion falls roughly ~14% per decade after the third decade; IGF-1 tracks downward in parallel. Secretagogue responsiveness is described as preserved in many healthy older cohorts—still not an endorsement for unsupervised use.

  • GH decline: ~14% / decade (population modeling)
  • IGF-1 decline: parallel trajectory
  • Elderly pharmacodynamic response: generally maintained in cited volunteer work

Safety profile from research

What early-phase trials and reviews emphasize

Both moieties show dose-related, usually mild events in the public trial corpus. Ipamorelin's hormone selectivity is the recurring differentiator versus legacy GHRP chemistry.

Frequently cited mild events

20%

Injection site

Mild
15%

Flushing / warmth

Mild
12%

Headache

Mild
8%

Dizziness

Mild
5%

Nausea

Mild
Key safety feature

Ipamorelin selectivity

Compared with older GHRPs, ipamorelin is not associated in trial panels with:

  • Cortisol — limited stress-axis activation
  • ACTH — reduced adrenal drive vs non-selective GHRPs
  • Prolactin — avoids prolactin-linked adverse narratives
  • Aldosterone — less mineralocorticoid-related fluid retention
Discontinuation & tolerability

Trial-friendly summaries

CJC-1295 (30–60 mcg/kg)Generally well tolerated
Ipamorelin (0.01–0.1 mg/kg)No SAEs in cited acute studies
  • Serious adverse events were uncommon in available Phase I/II disclosures.
  • No withdrawal syndrome is described after cessation in review summaries.
  • Pharmacodynamic effects wane as peptides clear—reversibility is the default assumption.
Trial exclusions (research planning)

Common contraindication themes

Active malignancy or cancer historyDiabetic retinopathyPregnancy / breastfeedingPituitary disordersPeptide hypersensitivity
Theoretical concerns
  • Long-term sequelae of sustained GH/IGF-1 elevation remain incompletely mapped outside specialty care.
  • Glucose metabolism may shift in diabetic or insulin-resistant models—monitor per protocol.
  • Theoretical proliferative risk is debated whenever IGF-1 is chronically raised—high-risk cohorts need bespoke oversight.

Storage handling reference

Peptide handling

Cold

Lyophilized: store per COA / SOP.

Reconstitution

Sterile water or buffer per monograph.

Light

Limit exposure during aliquoting.

Aliquot

Minimize freeze-thaw for both peptides.

Researcher notes

  • Early-phase data overall support a favorable acute safety story—still not equivalent to long-term surveillance.
  • Ipamorelin's selectivity lowers several classic GHRP adverse-effect narratives but does not remove all risks.
  • No-DAC CJC-1295 is intentionally shorter-acting; depot formulations behave differently in PK/PD reviews.
  • Map every statistic back to the primary manuscript—review articles compress heterogeneous cohorts.

Important Research Notice

Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.